secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2024-10-24T23:59:59+00:00
Accession:  0001193125-24-242960
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant appoints Roberto Mignone (Bridger Management) to board of directors
----------------------------------------------------------------------------

- Guardant expands board to 10; appoints Roberto Mignone as Class I director effective Oct 21, 2024.
- Founder and Managing Partner of Bridger Management, a healthcare-focused investment firm.
- Appointed to audit committee; receives initial equity awards totaling $725,000 vesting over 4 years.
- Appointment follows FDA approval of Shield blood test for early-stage colorectal cancer screening.
- Also serves on Teva Pharmaceuticals board and as co-Vice Chairman of NYU Langone Medical Center.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000119312524242960/0001193125-24-242960-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000119312524242960/d763358d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-242960

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer